Efficacy of Icotinib for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified

Background and objective As the first epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in China, icotinib shows promising anticancer activity in vitro and vivo. The phase III clinical study (ICOGEN) showed that icotinib has a good efficacy and tolerability in Chinese patients wi...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Yiping ZHANG, Beibei ZHANG, Chunxiao HE, Baochai LIN, Lan SHAO, Jufen CAI, Xinmin YU, Zhengbo SONG
Формат:	Artigo
Хэл сонгох:	Chinês
Хэвлэсэн:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2013-03-01
Цуврал:	Chinese Journal of Lung Cancer
Нөхцлүүд:	Lung neoplasms Icotinib EGFR mutation Efficacy
Онлайн хандалт:	http://dx.doi.org/10.3779/j.issn.1009-3419.2013.03.04
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!